Loading...
Novavax reported revenue of $178.8 million and a net loss of $322.4 million, or $4.31 per share, for the third quarter of 2021.
Gained first regulatory approval for COVID-19 vaccine.
Prepared to deliver vaccine globally with additional regulatory submissions.
Encouraging results from six-month booster study complement strong efficacy demonstrated by NVX-CoV2373.
Confident that vaccine will serve as an important tool to fight COVID-19 in the years to come.
Analyze how earnings announcements historically affect stock price performance